Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investigator/Firm Financial Ties May Trigger Heavier Scrutiny Of Data By FDA

This article was originally published in The Tan Sheet

Executive Summary

Disclosure of financial arrangements between a clinical investigator and study sponsor will lead to a more stringent product review at FDA, Office of Drug Evaluation I Associate Director-Regulatory Affairs Linda Carter told the Food & Drug Law Institute.

You may also be interested in...



OTC "Actual Use Studies" Subject To Financial Disclosure Requirements

"Actual use studies" conducted in support of Rx-to-OTC switch or direct-to-OTC new drug applications and used to show effectiveness in the OTC setting are subject to FDA's financial disclosure requirements, according to a draft guidance clarifying the agency's February 1998 final rule.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS091332

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel